Search This Blog

Thursday, April 2, 2026

Lipocine Phase 3 trial of LPCN 1154 in postpartum depression misses primary endpoint

 

 post hoc analysis shows benefit signals

  • Lipocine is evaluating next steps for LPCN 1154 in postpartum depression after the failed Phase 3.
  • The company plans to seek FDA breakthrough therapy and fast track designations for LPCN 1154.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)